콘텐츠로 건너뛰기
Merck

860693P

Avanti

C24:0 Ceramide (d18:2(4E,8Z)/24:0)

Avanti Research - A Croda Brand

동의어(들):

N-lignoceroyl-D-erythro-sphingosine (d18:2(4E,8Z) base)

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C42H81NO3
Molecular Weight:
648.10
UNSPSC Code:
12352211
NACRES:
NA.25
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


제품 이름

C24:0 Ceramide (d18:2(4E,8Z)/24:0), Avanti Research - A Croda Brand 860693P, powder

assay

>99% (TLC)

form

powder

packaging

pkg of 1 × 1 mg (860693P-1mg)

manufacturer/tradename

Avanti Research - A Croda Brand 860693P

lipid type

sphingolipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

OC[C@@](NC(CCCCCCCCCCCCCCCCCCCCCCC)=O)([H])[C@]([H])(O)/C=C/CC/C=C\CCCCCCCCC

InChI

1S/C42H81NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h27,29,35,37,40-41,44-45H,3-26,28,30-34,36,38-39H2,1-2H3,(H,43,46)/b29-27-,37-35+/t40-,41+/m0/s1

InChI key

ZCUCZYYSYGKQQV-PZYFEVQHSA-N

General description

C24:0 Ceramide (d18:2(4E,8Z)/24:0), also known as N-lignoceroyl-D-erythro-sphingosine (d18:2(4E,8Z) base), is a very long chain plasma ceramide derived from sphingosine containing two double bonds with lignoceric acid.

Biochem/physiol Actions

Altered levels of C24:0 Ceramide has been observed in mild cognitive impairment (MCI) patients. It acts as a primary biomarker of Alzheimer disease (AD) progression.

Packaging

5 mL Amber Glass Screw Cap Vial (860693P-1mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC


저장 등급

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



Michelle M Mielke et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 6(5), 378-385 (2010-09-04)
A blood-based biomarker of Alzheimer's disease (AD) would be superior to cerebrospinal fluid (CSF) and neuroimaging measures in terms of cost, invasiveness, and feasibility for repeated measures. We previously reported that blood ceramides varied in relation to timing of memory



국제 무역 품목 번호

SKUGTIN
860693P-1MG04061835319176